/
PVLA
$154.84+$6.63 (+4.47%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.1B
14M shares
52-week range
$21.55 – $155.00
100% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.54%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$142.01
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $31.4M | $25.9M | $0 | $0 | $0 |
| Cost of revenue | $2.4M | $2.8M | $0 | $0 | $0 |
| Gross profit | $29.1M | $23.1M | $0 | $0 | $0 |
| Gross margin | 92.5% | 89.3% | — | — | — |
| R&D | $64.2M | $50.2M | $8.8M | $8.2M | $22.8M |
| Operating income | −$51.8M | −$43.5M | −$11.9M | −$14.1M | −$38.6M |
| EBITDA | −$43.4M | −$30.5M | $18.7M | −$13.1M | −$35.9M |
| Net income | −$45.7M | −$33.3M | $18.7M | −$17.4M | −$41.7M |
| Net margin | -145.6% | -128.5% | — | — | — |
| EPS (diluted) | -56.69 | -29.61 | 14.74 | -7.83 | -3.71 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $26667 | $-5.56 | $-6.56–$-3.65 | 11 |
| 2027 | $31M | $-6.43 | $-8.35–$-4.42 | 9 |
| 2028 | $147M | $-2.46 | $-8.76–$7.64 | 8 |
| 2029 | $349M | $5.64 | $0.70–$13.39 | 6 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.71
Price
$154.84
Implied downside
-97%
Peer comparison
Palvella Therapeutics, Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
www.palvellatx.com- Employees
- 29
- IPO / List date
- Dec 16, 2024
- HQ
- WAYNE, PA
Held by traders on TradeandTell
No one on the platform currently holds PVLA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 17,970 | $2.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PVLA yet.
